- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars | 1 | Benzinga.com | ||
| Do | Enliven Therapeutics meldet positive Phase-1b-Daten für CML-Medikament ELVN-001 | 2 | Investing.com Deutsch | ||
| Do | Enliven reports positive initial phase 1b data for ELVN-001 in CML | 1 | Investing.com | ||
| Do | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | 71 | PR Newswire | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| Mi | Enliven Therapeutics beruft Scott Garland vor entscheidender CML-Studie in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| Mi | Scott Garland joins Enliven Therapeutics board as company prepares for CML trial | 1 | Investing.com | ||
| Mi | Enliven Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.12.25 | Enliven Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.12.25 | Enliven Therapeutics appoints Rick Fair as new CEO | 1 | Investing.com | ||
| 11.12.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces New CEO to Drive Next Phase of Development | 167 | PR Newswire | Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer
Co-Founder Sam... ► Artikel lesen | |
| 11.12.25 | Enliven Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update | 167 | PR Newswire | Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML
Remains on track to initiate Phase 3 pivotal trial of ELVN-001... ► Artikel lesen | |
| 12.11.25 | Enliven Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.08.25 | Enliven Therapeutics, Inc Q2 Loss Climbs | 1 | RTTNews | ||
| 13.08.25 | Enliven Therapeutics GAAP EPS of -$0.49 beats by $0.04 | 2 | Seeking Alpha | ||
| 13.08.25 | Enliven Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.08.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | 322 | PR Newswire | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| 13.06.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | 462 | PR Newswire | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| 14.05.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | 615 | PR Newswire | Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June
EHA abstract reported cumulative MMR rate... ► Artikel lesen | |
| 14.05.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress | 740 | PR Newswire | Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 4,212 | 0,00 % | Morgen-Update: Breaking: Valneva durchstartet - jetzt wird's richtig spannend | ||
| BIOFRONTERA | 2,520 | -0,40 % | Biofrontera erreicht wichtigen Meilenstein bei Studien zu Hauttherapien | ||
| CRISPR THERAPEUTICS | 49,400 | +1,65 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | NSE - Affimed N.V. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| DENALI THERAPEUTICS | 14,820 | +1,13 % | Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up | ||
| FATE THERAPEUTICS | 0,901 | -1,40 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ||
| AGIOS | 24,200 | 0,00 % | Vanda's motion sickness drug, Agios' thalassemia treatment make the grade with FDA | ||
| CELLECTIS | 3,830 | -2,54 % | Cellectis Announces 2026 Strategy and Catalysts | NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,510 | +0,57 % | Voyager Therapeutics, Inc. - 8-K, Current Report | ||
| UNIQURE | 23,960 | +20,49 % | uniQure Inc.: uniQure Announces Type A Meeting Scheduled with FDA | LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting... ► Artikel lesen | |
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 21,460 | 0,00 % | TECX, GKOS, GH, ALGN, NMRA Surge After Hours On Clinical Data And Earnings | WASHINGTON (dpa-AFX) - Several healthcare and life sciences names posted notable gains in after-hours trading, driven by clinical updates, earnings releases, and in some cases, unexplained momentum.Tectonic... ► Artikel lesen | |
| SCILEX | 13,290 | 0,00 % | Oramed-Aktie steigt nach Millionenzahlung von Scilex und Dividendenankündigung | ||
| ALLOGENE THERAPEUTICS | 1,495 | 0,00 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T | 1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with... ► Artikel lesen | |
| NUVATION BIO | 8,450 | 0,00 % | Nuvation Bio: UBS nimmt Coverage mit "Neutral"-Rating auf |
Das Unternehmen ENLIVEN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 23,280 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENLIVEN THERAPEUTICS INC finden Sie auf Wallstreet Online.